Pharma Business - September 23, 2013
Orexo announces the approval of Abstral in Japan
Orexo AB has announced the approval of Abstral (fentanyl) sublingual tablets in Japan. The product has been registered and will be sold by Kyowa Hakko Kirin Co., Ltd. Based on the agreement, the approval will trigger a milestone payment to Orexo. Kyowa Hakko Kirin and its subsidiaries have the rights for Abstral in all markets […]
Drug Development Pharma - February 27, 2013
Orexo enters research agreement with AstraZeneca
The two companies have entered an agreement regarding a preclinical program for a potential novel treatment of respiratory diseases (OX-CLI). Orexo grants to AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program, subject to a full […]